Literature DB >> 21255742

Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 2.

Sudha Seshadri1, Alexa Beiser, Rhoda Au, Philip A Wolf, Denis A Evans, Robert S Wilson, Ronald C Petersen, David S Knopman, Walter A Rocca, Claudia H Kawas, Maria M Corrada, Brenda L Plassman, Kenneth M Langa, Helena C Chui.   

Abstract

This article focuses on the effects of operational differences in case ascertainment on estimates of prevalence and incidence of cognitive impairment and/or dementia of the Alzheimer type. Experience and insights are discussed by investigators from the Framingham Heart Study, the East Boston Senior Health Project, the Chicago Health and Aging Project, the Mayo Clinic Study of Aging, the Baltimore Longitudinal Study of Aging, and the Aging, Demographics, and Memory Study. There is a general consensus that the single most important factor determining prevalence estimates of Alzheimer's disease (AD) is the severity of cognitive impairment used as a threshold to define cases. Studies that require a level of cognitive impairment in which persons are unable to provide self-care will have much lower estimates than the studies aimed at identifying persons in the earliest stages of AD. There are limited autopsy data from the aforementioned epidemiological studies to address accuracy in the diagnosis of etiological subtype, namely the specification of AD alone or in combination with other types of pathology. However, other community-based cohort studies show that many persons with mild cognitive impairment and also some persons without dementia or mild cognitive impairment meet pathological criteria for AD, thereby suggesting that the number of persons who would benefit from an effective secondary prevention intervention is probably higher than the published prevalence estimates. Improved accuracy in the clinical diagnosis of AD is anticipated with the addition of molecular and structural biomarkers in the next generation of epidemiological studies. Copyright Â
© 2011 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21255742      PMCID: PMC3039838          DOI: 10.1016/j.jalz.2010.12.002

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  73 in total

1.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

2.  Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.

Authors:  M Lorenzi; M Donohue; D Paternicò; C Scarpazza; S Ostrowitzki; O Blin; E Irving; G B Frisoni
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

Review 3.  Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies.

Authors:  I G McKeith; E K Perry; R H Perry
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

4.  Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series.

Authors:  A Lim; D Tsuang; W Kukull; D Nochlin; J Leverenz; W McCormick; J Bowen; L Teri; J Thompson; E R Peskind; M Raskind; E B Larson
Journal:  J Am Geriatr Soc       Date:  1999-05       Impact factor: 5.562

5.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

6.  Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease.

Authors:  M Albert; L A Smith; P A Scherr; J O Taylor; D A Evans; H H Funkenstein
Journal:  Int J Neurosci       Date:  1991-04       Impact factor: 2.292

7.  Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975.

Authors:  E Kokmen; C M Beard; K P Offord; L T Kurland
Journal:  Neurology       Date:  1989-06       Impact factor: 9.910

8.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

9.  Diagnostic criteria for primary neuronal degeneration of the Alzheimer's type.

Authors:  C Eisdorfer; D Cohen
Journal:  J Fam Pract       Date:  1980-10       Impact factor: 0.493

10.  The neuropathology of older persons with and without dementia from community versus clinic cohorts.

Authors:  Julie A Schneider; Neelum T Aggarwal; Lisa Barnes; Patricia Boyle; David A Bennett
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more
  36 in total

1.  Are clinical diagnoses of Alzheimer's disease and other dementias affected by education and self-reported race?

Authors:  Jeanne A Teresi; Ellen Grober; Joseph P Eimicke; Amy R Ehrlich
Journal:  Psychol Assess       Date:  2012-02-06

2.  A multi-state model based reanalysis of the Framingham Heart Study: Is dementia incidence really declining?

Authors:  Nadine Binder; James Balmford; Martin Schumacher
Journal:  Eur J Epidemiol       Date:  2019-10-14       Impact factor: 8.082

Review 3.  Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.

Authors:  Peter T Nelson; Elizabeth Head; Frederick A Schmitt; Paulina R Davis; Janna H Neltner; Gregory A Jicha; Erin L Abner; Charles D Smith; Linda J Van Eldik; Richard J Kryscio; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-04-24       Impact factor: 17.088

4.  Methionine Sulfoxide Reductase-B3 Risk Allele Implicated in Alzheimer's Disease Associates with Increased Odds for Brain Infarcts.

Authors:  Sarah C Conner; Laurent Benayoun; Jayandra J Himali; Stephanie L Adams; Qiong Yang; Charles DeCarli; Jan K Blusztajn; Alexa Beiser; Sudha Seshadri; Ivana Delalle
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 5.  Is synaptic loss a unique hallmark of Alzheimer's disease?

Authors:  Stephen W Scheff; Janna H Neltner; Peter T Nelson
Journal:  Biochem Pharmacol       Date:  2014-01-09       Impact factor: 5.858

6.  Cerebral microbleeds and risk of incident dementia: the Framingham Heart Study.

Authors:  José R Romero; Alexa Beiser; Jayandra J Himali; Ashkan Shoamanesh; Charles DeCarli; Sudha Seshadri
Journal:  Neurobiol Aging       Date:  2017-03-06       Impact factor: 4.673

7.  Cognitive Function in Low-Income and Low-Literacy Settings: Validation of the Tablet-Based Oxford Cognitive Screen in the Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South Africa (HAALSI).

Authors:  Glyn W Humphreys; Mihaela D Duta; Livia Montana; Nele Demeyere; Cathal McCrory; Julia Rohr; Kathleen Kahn; Stephen Tollman; Lisa Berkman
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2016-10-21       Impact factor: 4.077

Review 8.  Contributions of the Framingham Heart Study to stroke and dementia epidemiologic research at 60 years.

Authors:  Philip A Wolf
Journal:  Arch Neurol       Date:  2012-05

9.  Practical risk score for 5-, 10-, and 20-year prediction of dementia in elderly persons: Framingham Heart Study.

Authors:  Jinlei Li; Matthew Ogrodnik; Sherral Devine; Sanford Auerbach; Philip A Wolf; Rhoda Au
Journal:  Alzheimers Dement       Date:  2017-06-13       Impact factor: 21.566

10.  How technology is reshaping cognitive assessment: Lessons from the Framingham Heart Study.

Authors:  Rhoda Au; Ryan J Piers; Sherral Devine
Journal:  Neuropsychology       Date:  2017-11       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.